
Primaire tabs
Exporteer 89 resultaten:
Filters: Auteur is Wim Van Molle
Advancing regulatory dialogue: In silico models for improved vaccine biomanufacturing - an expert meeting report.,
, Vaccine, 2025 May 22, Volume 56, (2025)
DNA templates for the preparation of mRNA substances (5.40),
, 1/07/2025, Volume European Pharmacopoeia (Ph. Eur.) 12.1, (2025)
mRNA Substances for the production of mRNA vaccines for human use (5.39),
, 1/07/2025, Volume European Pharmacopoeia (Ph. Eur.) 12.1, (2025)
mRNA vaccines for human use (5.36),
, 1/07/2025, Volume European Pharmacopoeia (Ph. Eur.) 12.1, (2025)
The Role of EDQM and OMCLs,
, Training "Responsable des affaires réglementaires", 14/03/2025, Issue Culture in vivo ASBL, (2025)
Session Chair: "Panel discussion: Feedback from regulators on Stability models",
, Second Regulatory Workshop on Utilizing In Silico Models to Expedite Vaccine Development, Testing, and Lifecycle Management, 27/05/2025, Brussels, Belgium, (2025)
Accelerating vaccine manufacturing development through model-based approaches: current advances and future opportunities,
, Current Opinion in Chemical Engineering, Volume 43, (2024)
Advanced GMP/CMC,
, Capacity Building for vaccine manufacturers in Iran, 29/10/2024, Issue European Centre for Clinical Research Training, (2024)
Communication on out of specification results for vaccine Drug Substances,
, Annual OMCL Meeting, OCABR Vaccin Session, 16/05/2024, Issue EDQM, Ohrid, North Macedonia, (2024)
Ethical approval for controlled human infectious model clinical trial protocols - A workshop report.,
, Biologicals, 2024 Feb, Volume 85, (2024)
EU Annual report : batch release of human vaccines,
, 01/04/2024, Brussels, Belgium, p.261, (2024)
Maintaining the quality of vaccines through the use of standards: Current challenges and future opportunities.,
, Biologicals, 2024 Mar 12, Volume 86, (2024)
Regulatory workshop on challenge strain development and GMP manufacture - A stakeholder meeting report.,
, Biologicals, 2024 Feb, Volume 85, (2024)
The Role of EDQM and OMCLs,
, Training « Responsable des affaires réglementaires », 24/01/2024, Issue Culture in vivo ASBL, (2024)
Closing Session: Health Emergencies Preparedness for the Future Panel Discussion,
, 2023 PDA BioManufacturing Conference Agility and Biomanufacturing Excellence to Meet Patients’ Needs, 13/09/2023, Issue PDA, (2023)
Development of a multiplex-based immunoassay for the characterization of diphtheria, tetanus and acellular pertussis antigens in human combined DTaP vaccines.,
, J Immunol Methods, 2023 Jun, Volume 517, (2023)
EU batch release procedure: Annual Report 2 - Batch Release of Vaccines,
, 2023 05 25, p.314, (2023)
The IMI Inno4Vac project: a public-private partnership focussing on Innovations to accelerate vaccine development and manufacture,
, 2023 PDA BioManufacturing Conference Agility and Biomanufacturing Excellence to Meet Patients’ Needs, 12/09/2023, Issue PDA, Seville, Spain, (2023)
Rational arguments for regulatory acceptance of consistency testing: benefits of non-animal testing over release testing of vaccines.,
, Expert Rev Vaccines, 2023 Apr 03, Volume 22, Issue 1, Number 377, (2023)
Regulatory expectations on the use of vaccine reference standards for maintaining product quality.,
, Maintaining the Quality of Vaccines through the Use of Standards: Current Challenges and Future Opportunities, 21/06/2023, Issue IABS, Ottawa, Canada, (2023)
Regulatory progress and future plans,
, Inno4Vac 2nd annual meeting 2023, 5/10/2023, Lyon, France, (2023)
The Role of EDQM and OMCLs,
, Responsable des affaires réglementaires, 26/01/2023, Issue Culture in vivo ASBL, (2023)
Round table discussion,
, Maintaining the Quality of Vaccines through the Use of Standards: Current Challenges and Future Opportunities, 22/06/2023, Issue IABS, Ottawa, Canada, (2023)
Training on the assessment of quality part (M3) of the eCTD for the registration of vaccines for human use,
, Training on The assessment of quality part (M3) of the eCTD for the registration of vaccines for human use, 15/11/2023, Brussels, Belgium, (2023)
What do we request for production and quality control of CHIM strains.Should it be GMP or is adherence to GMP acceptable ?,
, Ethical Approval for CHIM Clinical Trial Protocols, 30/05/2023, Brussels, Belgium, (2023)